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Minoxidil an orally administered, peripheral va-
sodilator used to treat hypertension, causes hypertri-
chosis in more than 80% of users. The drug reduces
elevated blood pressure by decreasing peripheral
vascular resistance. Chemically, minoxidil is 2,4-di-
amino-6-piperidinopyrimidine-3-oxide; it is soluble in
water to the extent of approximately 2 mg/ml, is
more readily soluble in propyiene glycol or ethanol,
and is nearly insoluble in acetone, chloroform, or
ethyf acetate. Following oral administration of minox-
idil and in association with the reduction in peripheral
vascular resistance, cardiac output is augmented, salt
and water are retained, and plasma renin activity
rises.''
When taken orally, minoxidil is at least 90% ab-
sorbed from the human gastrointestinal tract. After
one 5-mg tablet of minoxidil, blood levels of the
parent drug reach a maximum of 156.6 ng/ml within
the first hour and decline rapidly thereafter to 1.5
ng/ml within 24 hours (Table 1). The average plasma
half-life in humans is 4.2 hours for the combination
of parent drug and its metabolites. About 90% of
administered drug is metabolized, predominantly by
conjugation with glucuronic acid,^ '' and parent drug
and metabolites are principally excreted in the urine.
Minoxidil does not bind to plasma proteins, and its
renal clearance corresponds to the glomerular filtration
rate. In the absence of functional renal tissue, minox-
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idtl and its metabolites can be removed by hemodi-
alysis.
Fluid retention and hypertrichosis are the most
commonly occurring side effects of minoxidil. Hair
regrowth in a patient with male pattern baldness was
described in a case report of a hypertensive patient
treated twice daily with 20 mg oral minoxidil.'' The
extensive hair regrowth continued after 10 months
of therapy. New and increased hair growth as a side
effect was also detected in an early clinical study
involving five of eight patients on oral minoxidil
therapy for 2 months/ Zappacosta* reported reversal
of baldness in a patient on minoxidil for the treatment
of hypertension.
After the third week of therapy with oral minoxidil,
hypertrichosis usually appears between the eyebrows
and the hair line, in the malar and temporal areas,
on the backs of the arms, on the shoulders, and on
the legs. Hair growth has been noted at all dose
levels, although it appears later and is less marked
after the smaller doses of 10 mg or less per day. New
hair growth ceases abruptly when minoxidil therapy
is discontinued, but the patient's appearance does
not return to normal for several months. Normal
hormonal assays were recorded in 50 patients who
received minoxidil for 1 year or longer,"'* and we do
not believe that excessive hair growth is a result of
an endocrine abnormality.
Overview of Efficacy and Safety
Dermal acute toxicity studies in rats have shown
that minoxidi! is not toxic when applied 10 mg/rat/
day and Is slightly toxic at 30 mg/rat/day and 60
mg/rat/day. While no gross or microscopic lesions
were found in the rat skin, the pharmacologic effects
included dose-related decreases in hemoglobin, de-
creased erythrocyte counts, decreases in serum so-
dium and chloride levels, and increases in serum
cholesterol and heart and liver weight.
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TABLE 1. Mean Minoxidil Blood Levels from 20 Patients After Ingestion of One 5-mg Tablet
Hours

















We are conducting the clinical research program
for topical minoxidil slowly and with caution because
of the potent action of the systemic formulation of
minoxidil on the cardiovascular system in hypertensive
patients. Initially, three 14-week studies involved
daily bilateral applications of 1%, 3%, or 5% minoxidil
to circular areas 2 cm in diameter on the scalps of
patients with male pattern baldness. As expected, no
systemic side effects were observed. There was some
evidence of hair growth stimulation, appreciably de-
layed and variable in occurrence among patients.
Long-term clinical studies of 6-12 months were
started in 1980 and 1981. Since then, several clinical
studies have been completed and new ones started.
For example, in one open-label study, we evaluated
the effectiveness of twice-daiiy unoccluded applica-
tions of 5% minoxidil in men and women with
alopecia areata and alopecia androgenetica. Therapy
was scheduled for 6 months in alopecia areata and
for 1 year in pattern baldness. Stimulation of hair
growth ranged from minimal early evidence to appre-
ciable restoration toward typical terminal scalp hair.
It took 3-8 months to obtain the more definitive
evidence of stimulated hair growth. Other investiga-
tors who used a topically applied solution of 1%
minoxidil in three patients with alopecia areata un-
responsive to conventional treatments found local
hair regrowth in the area of application within 4-6
weeks in two of the patients.'"
Fenton and Wilkinson" induced hair growth in 22
of 30 (80.8%) patients with alopecia areata after 6
months of twice-daiiy topical applications of 1 %
minoxidil lotion or ointment. Sixteen of these patients
grew acceptable terminal hair.
In a double-blind study, Headington and
treated 21 healthy men with pattern baldness with
twice-daily topical applications of 1% or 5% minoxidil
or the vehicle for minoxidii (water-propyiene glycol-
alcohol). The shortest and longest hairs measured
were recorded for each treatment site through study
week 25 (Table 2). Medications were applied only
for 15.7 weeks (110 successive days), and no medi-
cation was applied during weeks 16-25. Results were
expressed as the difference between an individual's
minimum and maximum lengths of hair at baseline
and at each evaluation period. A minimal increase in
mean hair length was seen in al! treatment groups,
including the placebo group, between weeks 3-9
and at week 25. There were no statistically significant
differences among the groups in the hair growth
during the 12-week medication period.
After 15.7 weeks of treatment in this study, clinical
and statistical evaluations of the blood chemistries,
CBC, urinalysis, and EKG were similar for subjects
receiving the 1% or 5% solutions of minoxidil and
those receiving the placebo vehicle, nor was there a
difference between mean pre- and postmedication
values in blood pressure, pulse rate, and body weights
in these subjects. Mild stinging, burning, itching, and
erythema were noted only after the evaluation at
week 2 in 11 of 21 subjects (2 receiving 1% minoxidil,
4 receiving 5% minoxidil, and 5 receiving the vehicle).
These effects were thought to be due to the vehicle.
Absorption and Excretion After Topical Minoxidil
In animal and human topical absorption studies,
we have used 1%, 3%, and 5% minoxidil in a
propyiene glycol-ethanol-water vehicle. When ve-
hicles containing propyiene glycol-alcohol-water
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Single application after 9 daily applications
Single application











Derived from the percentage of applied dose of labeled drug excreted in urine and stool.
were used, the in vitro transport data over 72 hours
showed a cumulative penetration of 3.0 mg, 3.7 mg,
and 4.0 mg oi drug from the 1%, 3%, and 5%
minoxidil solutions, respectively. The extent of per-
cutaneous absorption in the rat and monkey, based
upon the percentage of the applied dose of '''C-
minoxidil excreted in the urine and stool, is shown
in Table 3. In the rat and monkey, the skin of the
application sites retained 30-78% of the applied
dose of '•'C-minoxidil.
In ongoing clinical trials with topical minoxidil in
patients with alopecia areata and alopecia androge-
netica or both, we are using applications of 1%, 3%,
and 5% minoxidil solutions once daily with or without
overnight occlusion. After therapy ranging from a few
months to 1 year in 150 patients, single-point and
variable time values of serum minoxidii in six patients
so tested at 2, 4, and 8 weeks tended to range from
nondetectable levels (radioimmunoassay sensitivity
of 1.4 ng/ml) to a maximum of 6.2 ng/ml. In a
double-blind study of 21 men with pattern baldness,'^
a radioimmunoassay with a sensitivity of 1.4 ng/ml
showed no consistency or trend in minoxidil serum
levels (Table 4). The highest levels of minoxidil (6.2
ng/ml} occurred in the 5% minoxidi! group at week
2. One subject in the 1% minoxidil group had a
serum level of 2.3 ng/ml minoxidil at week 2.
In a percutaneous absorption/excretion study, 1%
or 5% solutions of '"'C-minoxidil were applied topi-
cally to the scalps of 12 healthy men. At either dose,
minoxidil was poorly absorbed through the skin. The
mean recovery of the applied doses in the urine was
less than 4% (Table 5). A fecal analysis was done in
six of these volunteers and no radioactivity was
TABit 4, Minoxidil Serum Levels' (ng/ml) in 2t Men with Pattern Baldness



































• Radioimmunoassay (sensitivity of 1.4 ng/ml) of serum drawn in mornins before breakfast, about 10-12 hours after topical application
of treatment solution.
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detected. A mean of 43-45% of the 1 % and 5%
applications of radioactive minoxidii was recovered
from the surface of the skin (Table 6). The total
recovery of '''C-mrnoxidil in this study ranged from
42.9% to 47.2% for either dose at any of the test
periods. We presume that the remaining material
was lost from the surface of the skin to the environ-
ment. We evaluated the possibility that a portion of
applied minoxidil is bound within the skin and slowly
released to the systemic circulation, where it might
be below the limits of detection used in this study.
Biopsied tissue of the scalp from five patients 24
hours after the second treatment showed radioactivity
of 0.0001% to .0015%.
Effect of Topical Minoxidil on Blood
Flow of the Scalp
Burton and co-workers^'•'•' postulated increased
cutaneous perfusion with potent peripheral vasodi-
lators. It has been suspected for a long time that
localized hypertrichosis is associated with increased
cutaneous blood flow in some cutaneous inflamma-
tory conditions as well as with arteriovenous aneu-
In another double-blind study, we tested 0%, 1%,
3%, and 5% randomly assigned solutions of minoxidil
on the balding scalps of 16 human volunteers. On 2
consecutive days, an 0.25 ml volume of the formu-
lations was uniformly spread over 100 cm'' of the
bald scalp. After 15 minutes, cutaneous blood flow
was recorded continuously for 40-60 minutes, then
intermittently for 4 hours. A single microcirculatory
flow parameter was measured by laser Doppler ve-
locimetry (LDV),'" "̂ and changes in microcirculatory
blood volume were measured by photopulse pleth-
ysmography (PPG).^'"
The 5% minoxidil solution increased blood flow
when compared with the other treatments. As shown
by LDV, on day 1 (Fig. 1) there was a statistically
significant increase (p = 0.0001) in mean blood flow
within 15 minutes of application; that flow was main-
tained at least through 1 hour. On day 2 (Fig. 2),
blood flow stimulation increased (p = 0.0001) three-
fold within 15 minutes of application and remained
that way for about 1 hour. With the photopulse
plethysmography technique, the mean blood perfu-
sion response was statistically significant (p = 0.01)
only for application of the 5% minoxidil solution on
day 2.
TABLE 6. Recovery of '*C-Minoxidil (% of Dose) from Surface of tbe Skin in Normal Subjects




















































Subject used hair drier several hours after treatment was applied.
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Histopathologic Findings in the Scalp After Topical
Applications of Minoxidil
In a double-blind study by Headington and No-
vak,'^ a 1% or 5% minoxidil solution or placebo was
applied twice daily to three groups of seven healthy
men with pattern bladness. In all 21 patients, a
4-mm Baker disposable punch was used to obtain a
biopsy from the vertex or from the parietal areas of
the scalp pretreatment and at weeks 12 and 24.
Details of the histoiogic techniques used were pub-
lished by Headington.^* Qualitative evaluation showed
that biopsies obtained from individuals receiving ei-
ther topical minoxidil or placebo did not differ from
their pretreatment biopsies with respect to semi-
quantitative determination of inflammation. There
was no suggestion of a direct toxic or irritant effect
or of allergic contact dermatitis, nor was epidermal
hyperplasia or dyspiasia seen. The sebaceous epithe-
lium and papillary reticular dermis appeared unal-
tered. Morphologic changes were not found in blood
vessels, including vessels of the follicular dermal
papillae. The seven subjects who received the 5%
dose of minoxidil had a mean hair shaft diameter of
0.029 mm before treatment, which increased to
0.043 mm at 12 weeks and measured 0.042 mm at
24 weeks, although therapy was discontinued after
15.7 weeks. In this study, minoxidil and/or its vehicle
affected hair growth by induction or hypertrophy of
the existing follicles.
Quantitative data from this study show that we
can determine from transverse sections of a scalp
biopsy a patient's morphologic capability for response.
The identification of potential morphologic nonre-
sponders is, of course, essential to the study of
topical stimulation of hair growth.
Comment '
We are continuing an extensive program to evaluate
the safety and efficacy of topical minoxidil in certain
alopecias. In our studies to date, 1% and 5% solutions
of topically applied minoxidil induced hair growth in
some patients with alopecia areata {totalis, universalis)
and alopecia androgenetica. The onset of stimulation
of hair growth may be delayed 2-7 months, the
stimulated hairs are pigmented, and the increase
ranges from minimal to 3 cm or more. The positive
hair growth stimulation seen to date in our studies is
quite variable among patients. Some patients who
applied topically the higher (5%) concentrations of
minoxidil to the scalp showed hypertrichosis on the
face and extremities, suggesting a systemic side effect.
The mechanism by which minoxidil stimulates hair





FKJ. 1. Mean blood flow-time curve as shown by laser Doppler
vefocimetry (LDV) following day 1 application of 0%, 1%, 3%,
and 5% topical minoxidil lo bald scalps of four healthy men at
each dose.
is attributed to a direct vasodilatory effect of minoxidil
on the skin vasculature, but other mechanisms are
possible. More basic and clinical research data are
needed to assess the potential of topical minoxidil as
an agent to stimulate hair growth In patients with
alopecia areata and alopecia androgenetica; we are
accumulating these data in our ongoing or proposed
in vitro (tissue culture), animal, bioavailability, and
human studies. Meanwhile, prescription and use of
compounded topical minoxidil for alopecias in pre-
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FIC. 1. Mean blood flow-lime curve as shown by laser Doppler
velocimetry (LDV) following day 2 application of 0%, 1%, 3%,
and 5% (opical minoxidil to bald scalps of four healthy men at
each dose.
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Hay Fever Can Be Dangerous
During the two-week period of )uly 22 to August 8, 1982, five people experienced
anaphylactic reactions after sustaining skin-abrasion injuries while riding on an Alpine Slide in
Vermont. The slide is an amusement ride that consists of a free-running sled that glides down
a mountainside on an asbestos-cement track. A case-control study was initiated and included
companions of the index cases, noncompanions with abrasion injuries, and six employees who
had also had recent abrasion injuries from the slide. Risk factors that were significantly
associated with the development of anaphylaxis included abrasions, a personal or family history
of allergic complaints, and a history of symptoms of allergic rhinoconjunctivitis at the time of
the abrasion injury. A large number of grass-pollen grains and mold spores were identified at
the site of the slide, and all four index cases who had skin tests with grass pollens had positive
reactions. A review of past records on the index slide and 27 similar amusement slides In the
United States revealed 24 additional cases of anaphylactic reactions, 22 of which followed skin
abrasions occurring predominantly in late June to early August—the grass-pollination season in
the mountains. The evidence, although not conclusive, is consistent with the hypothesis that
this syndrome represents systemic anaphylaxis caused by pollen grains introduced into persons
who are allergic to grass through skin abrasions sustained while riding the amusement slides.—
Spitainy KC, Farnham }E, Witherell LE, et al. Alpine slide anaphyiaxis. N EngI) Med. 19d4;3W: 1034.

